A Photo Sparks a Trillion‑Dollar Shift: Whose House Did Elon Musk’s (马斯克) War Reach?

A single image, huge consequences

The GLP‑1 obesity-drug arms race that reshaped global pharma had an unlikely origin: it has been reported that a 2021 social post by Elon Musk helped turn semaglutide from a niche diabetes drug into a global weight‑loss phenomenon. The payoff has been immense. In 2025 Eli Lilly’s (礼来) tirzepatide pulled ahead with about $36.5 billion in sales versus Novo Nordisk’s (诺和诺德) $36.1 billion, a razor‑thin lead that crystallized a broader market upheaval and triggered a brutal price and patent fight—especially in China.

China became the decisive battleground

China is now the place where fortunes are won or lost. Reportedly, Novo Nordisk slashed some in‑hospital prices for semaglutide in December 2025 and Eli Lilly retaliated with far deeper cuts—one Lilly specification fell roughly 80% in some provinces—after the core semaglutide compound’s Chinese patent lapsed on March 20, 2026. Domestic makers have queued generic applications. Who benefits from the efficacy arms race when prices collapse and generics rush in? The answer: the company that can pair acceptable clinical performance with rapid, low‑cost commercialization.

Pfizer’s (辉瑞) China bet: lifeline or Hail Mary?

Enter Pfizer (辉瑞). It has been reported that Pfizer’s self‑developed GLP‑1 program collapsed after safety and tolerability setbacks, leaving the 177‑year‑old giant effectively productless in the category. Rather than double down on slow in‑house R&D, Pfizer spent heavily to buy capability: large acquisition of Metsera in 2025, other licensing deals, and reportedly a $495 million purchase of China commercial rights to enoglutide (埃诺格鲁肽) from Hangzhou Xianweida (杭州先为达). On March 6, 2026 Pfizer’s enoglutide secured Chinese approval — not by promising to beat the best data, but by being “good enough” and fast to market. Why China? Because much of the GLP‑1 market is out‑of‑pocket, allowing higher margins and avoiding some Western pricing constraints.

Market consequences and geopolitics

The result is a three‑way contest where technology, pricing, local manufacturing and distribution matter as much as headline efficacy numbers. It has been reported that Pfizer CEO Albert Bourla warned in 2024 that Pfizer “must participate and must win” in obesity — but this is as much about survival as ambition: COVID‑era revenue has collapsed and multiple blockbusters face patent cliffs. Analysts now predict a major reshuffle of the top pharma list by 2030. So who wins in the end? Not necessarily the company with the best data, but the one that ties clinical performance to rapid, efficient commercialization in China and navigates the geopolitics of patents, supply chains and cross‑border pricing.